Dr Rishabh Jain/X
Aug 20, 2026, 18:15
Rishabh Jain: MPNs May Finally Be Moving from Disease Control to Clonal Eradication
Rishabh Jain, Medical Oncologist at AIIMS Delhi, shared a post on X about a recent article by Isabelle Plo and William Vainchenker, published in NEJM, adding:
“MPNs may finally be moving from disease control to clonal eradication.
A new NEJM review highlights the biology reshaping treatment of ET, PV and myelofibrosis:
- More than 90% driven by JAK2, CALR or MPL mutations
- Driver mutations can arise decades before clinical disease
- Inflammation fuels clonal dominance, fibrosis and thrombosis
- Current therapy mainly controls counts, symptoms and thrombosis
- Next frontier: mutation-selective therapy
Most exciting:
- INCA033989, anti-mutant CALR antibody: hematologic and molecular responses in more than 90% of refractory or intolerant CALR-mutant ET in early data
- CALR×CD3 bispecifics and selective JAK2 V617F inhibitors are entering clinical development.
This could mark the shift from managing MPNs to eliminating the malignant clone.”
Title: Myeloproliferative Neoplasms
Authors: Isabelle Plo, William Vainchenker
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 8, 2026, 17:00Sally Mandour: Platelet Size And Shape Can Reveal The Diagnosis
-
Oct 8, 2026, 16:49Neil Morgan: Advancing Understanding Of Bleeding Disorders Of Unknown Cause
-
Oct 8, 2026, 16:38Beverley Hunt: Advancing Pulmonary Embolism Care Through Collaboration And Learning
-
Oct 8, 2026, 16:19Cedric Hermans: Six Webinars Advancing Haemophilia Care And Beyond
-
Oct 8, 2026, 16:09Luana Banu: Every Donation Connects A Human Chain
-
Oct 8, 2026, 15:51Khaled Musallam: A New Era In Thalassemia Care
-
Oct 8, 2026, 15:40Juan J. Ortiz։ Catheter Directed Therapy In Pulmonary Embolism
-
Oct 8, 2026, 15:34Petros Kountouris: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 8, 2026, 15:14Renzo Mancuso: Human Stem Cell Model Reveals Progenitor Fate in Tissue Macrophages